A near-autonomous AI chemist improves a challenging reaction in medicinal chemistry

OpenAI’s GPT-5.4, paired with Molecule.one, demonstrated a near-autonomous AI chemist that optimized a critical drug synthesis reaction. This milestone shows AI moving from research assistant to co-innovator in medicinal chemistry. For the 2026 AI economy, it signals accelerating drug discovery R&D costs downward, enabling faster small-molecule therapeutics. Companies lacking such autonomous lab capabilities risk falling behind in productivity and innovation.